Hubble Therapeutics closes USD 7.3 million Series A financing

Funds to be used for clinical advancement of HUB-101 gene therapy focused on rare eye diseases such as LCA16

Hanover, New Hampshire, March 25, 2025 - Hubble Therapeutics LLC announces the successful completion of a $7.3 million Series A financing round. The capital will be used to advance its promising gene therapy candidate HUB-101 into human clinical trials.

Hubble Therapeutics LLC ("HubbleTx") is a patient-centered biotechnology company dedicated to the development of innovative gene therapies for the treatment of inherited retinal diseases. The company's mission is to restore vision in patients with LCA16 and SVD through gene-based treatments, thereby improving the quality of life of affected families.

Innovative therapy for LCA16 and SVD

The gene therapy HUB-101 targets two rare and severe eye diseases: Leber congenital amaurosis (LCA16) and snowflake vitreoretinopathy (SVD). These genetic retinal diseases are caused by mutations in the KCNJ13 gene, which is responsible for the function of an essential ion channel in the pigment epithelial cells of the retina. The diseases usually occur in early childhood and lead to gradual blindness without effective therapy.

Over the past 20 years, my laboratory has been working on the development of curative gene therapies for severe pediatric blindness. HUB-101 now offers hope for affected patients and their families for the first time.

Dr. Bikash Pattnaik, Professor at the University of Wisconsin-Madison and Scientific Co-Founder of Hubble Therapeutics LLC

Scientific development and regulatory progress

The HUB-101 gene therapy was developed in the laboratory of Dr. Bikash Pattnaik at the University of Wisconsin-Madison School of Medicine and Public Health and licensed by the Wisconsin Alumni Research Foundation (WARF). It has already received Rare Pediatric Disease Designation and Orphan Disease Status from the FDA - important regulatory milestones on the way to market approval.

Hubble Therapeutics has teamed up with Andelyn Biosciences (Columbus, Ohio) and Virscio (New Haven, Connecticut) for further development and production. The first phase I/II clinical trials are planned for 2026 to evaluate the safety and efficacy of the therapy.

Strong partnerships for therapeutic success

WARF Ventures, one of the lead investors in the financing round, emphasizes the importance of the partnership between science and industry: "This groundbreaking research could restore vision to patients with rare eye diseases. We are proud to support Hubble Therapeutics as a co-lead investor and drive the development of this potentially life-changing therapy," says Greg Keenan, Senior Director, WARF Ventures & Accelerator

Future plans and commitment to patients

With the new funding, Hubble Therapeutics plans to scale up production of HUB-101 and fulfill the necessary requirements for IND (Investigational New Drug) approval. The goal is to begin clinical trials by 2026 and offer affected families worldwide a promising treatment option.

We thank our investors, scientists, partners and patient families who share our goal: To develop an effective therapy for LCA16 and SVD. We are determined to deliver on our promise and provide hope.

Jeff Sabados, Founder and President of Hubble Therapeutics LLC